On March 18, 2026, Enzon Pharmaceuticals, Inc. (the 'Company') filed a Form 8-K with the SEC, detailing the Tenth Amendment to the Section 382 Rights Agreement. This amendment modifies the Final Expiration Date of the rights issued under the agreement, extending it from noon, New York City time, on March 18, 2026, to noon, New York City time, on March 24, 2026. The amendment is part of a series of adjustments made to the Rights Agreement since its inception on August 14, 2020, aimed at preserving the Company's tax benefits. The management believes that this extension is in the best interests of the Company and its stockholders. The filing includes references to previous amendments and the complete text of the Tenth Amendment is attached as an exhibit. The Company continues to operate under the existing terms of the Rights Agreement, which remains unmodified except for the adjustment to the Final Expiration Date. This filing is categorized as administrative and does not indicate any significant changes in the Company's operational or financial status, thus maintaining a neutral impact on the stock price.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.